Research progress of chronic kidney injury in primary aldosteronism

Abstract

CLC Number:

R586.24

LAI Liqin, GONG Yanchun. Research progress of chronic kidney injury in primary aldosteronism[J]. Journal of Internal Medicine Concepts & Practice, 2023, 18(03): 211-214.

References40

[1]	Funder JW, Carey RM. Primary aldosteronism: where are we now? Where to from here?[J]. Hypertension, 2022, 79(4): 726-735. doi:10.1161/HYPERTENSIONAHA.121.18761 URL
[2]	国家卫生健康委高血压诊疗研究重点实验室学术委员会. 高血压患者中原发性醛固酮增多症检出、诊断和治疗的指导意见[J]. 中华高血压杂志, 2021, 29(6): 508-518.
[3]	Xu Z, Yang J, Hu J, et al. Primary aldosteronism in patients in China with recently detected hypertension[J]. J Am Coll Cardiol, 2020, 75(16): 1913-1922. doi:S0735-1097(20)34459-4pmid:32327102
[4]	Shrestha A, Che RC, Zhang AH. Role of aldosterone in renal fibrosis[J]. Adv Exp Med Biol, 2019, 1165: 325-346. doi:10.1007/978-981-13-8871-2_15pmid:31399972
[5]	Han HI, Skvarca LB, Espiritu EB, et al. The role of macrophages during acute kidney injury: destruction and repair[J]. Pediatr Nephrol, 2019, 34(4): 561-569. doi:10.1007/s00467-017-3883-1pmid:29383444
[6]	Yuan X, Wang X, Li Y, et al. Aldosterone promotes renal interstitial fibrosisviathe AIF-1/AKT/mTOR signaling pathway[J]. Mol Med Rep, 2019, 20(5): 4033-4044.
[7]	Barrera-Chimal J, Jaisser F. Vascular and inflammatory mineralocorticoid receptors in kidney disease[J]. Acta Physiol (Oxf), 2020, 228(2): e13390.
[8]	Barati A, Rahbar Saadat Y, et al. Eplerenone reduces renal ischaemia/reperfusion injury by modulating Klotho, NF-κB and SIRT1/SIRT3/PGC-1α signalling pathways[J]. J Pharm Pharmacol, 2022, 22: rgac054.
[9]	Luther JM, Fogo AB. The role of mineralocorticoid receptor activation in kidney inflammation and fibrosis[J]. Kidney Int Suppl (2011), 2022, 12(1):63-68.
[10]	Gifford CC, Lian F, Tang J, et al. PAI-1 induction during kidney injury promotes fibrotic epithelial dysfunctionviaderegulation of Klotho, p53, and TGF-β1-receptor signaling[J]. FASEB J, 2021, 35(7): e21725.
[11]	Brown NJ. Contribution of aldosterone to cardiovascular and renal inflammation and fibrosis[J]. Nat Rev Nephrol, 2013, 9(8): 459-69. doi:10.1038/nrneph.2013.110pmid:23774812
[12]	Gifford CC, Tang J, Costello A, et al. Negative regulators of TGF-β1 signaling in renal fibrosis; pathological mechanisms and novel therapeutic opportunities[J]. Clin Sci (Lond), 2021, 135(2): 275-303. doi:10.1042/CS20201213pmid:33480423
[13]	银锡靖, 覃诗婷, 杨柯. 骨桥蛋白在肾纤维化不同阶段中的作用研究进展[J]. 山东医药, 2018, 58(7): 105-107.
[14]	Spencer S, Wheeler-Jones C, Elliott J. Aldosterone and the mineralocorticoid receptor in renal injury: a potential therapeutic target in feline chronic kidney disease[J]. J Vet Pharmacol Ther, 2020, 43(3): 243-267. doi:10.1111/jvp.12848pmid:32128854
[15]	Hundemer GL, Curhan GC, Yozamp N, et al. Renal outcomes in medically and surgically treated primary aldosteronism[J]. Hypertension, 2018, 72(3): 658-666. doi:10.1161/HYPERTENSIONAHA.118.11568pmid:29987110
[16]	Monticone S, Sconfienza E, D’Ascenzo F, et al. Renal damage in primary aldosteronism: a systematic review and meta-analysis[J]. J Hypertens, 2020, 38(1): 3-12. doi:10.1097/HJH.0000000000002216pmid:31385870
[17]	Hajji M, Rais L, Kheder R, et al. Primary aldosteronism diagnosed in a patient with severe renal disease[J]. Tunis Med, 2018, 96(7): 454-457.
[18]	Halimi JM, Mimran A. Albuminuria in untreated patients with primary aldosteronism or essential hypertension[J]. J Hypertens, 1995, 13(12 Pt 2):1801-1802. pmid:8903655
[19]	Danforth DN Jr, Orlando MM, Bartter FC, et al. Renal changes in primary aldosteronism[J]. J Urol, 1977, 117(2): 140-144. doi:10.1016/s0022-5347(17)58376-7pmid:833953
[20]	李南方, 马轩, 王红梅, 等. 原发性醛固酮增多症患者蛋白尿情况分析[J]. 中华高血压杂志, 2013, 21(3): 249-252.
[21]	Chebotareva N, Bobkova I, Lysenko L, et al. Urinary markers of podocyte dysfunction in chronic glomerulonephritis[J]. Adv Exp Med Biol, 2021, 1306: 81-99. doi:10.1007/978-3-030-63908-2_6pmid:33959907
[22]	Liu D, Lv LL. New understanding on the role of proteinuria in progression of chronic kidney disease[J]. Adv Exp Med Biol, 2019, 1165: 487-500. doi:10.1007/978-981-13-8871-2_24pmid:31399981
[23]	Fernández-Argüeso M, Pascual-Corrales E, Bengoa Rojano N, et al. Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension[J]. Endocrine, 2021, 73(2): 439-446. doi:10.1007/s12020-021-02704-2pmid:33797699
[24]	姬文娜, 崔巍. 原发性醛固酮增多症患者早期肾脏损害相关临床因素分析[J]. 延安大学学报(医学科学版), 2017, 15(4): 19-22.
[25]	Petramala L, Concistrè A, Circosta F, et al. Evaluation of intra-renal stiffness in patients with primary aldosteronism[J]. High Blood Press Cardiovasc Prev, 2022, 29(1): 49-56. doi:10.1007/s40292-021-00485-3
[26]	Ogata H, Yamazaki Y, Tezuka Y, et al. Renal injuries in primary aldosteronism: quantitative histopathological analysis of 19 patients with primary adosteronism[J]. Hypertension, 2021, 78(2): 411-421. doi:10.1161/HYPERTENSIONAHA.121.17436 URL
[27]	Nakamura Y, Kobayashi H, Tanaka S, et al. Primary aldosteronism and obstructive sleep apnea[J]. Medicine (Baltimore), 2021, 100(11): e25049. doi:10.1097/MD.0000000000025049 URL
[28]	Nakamura Y, Kobayashi H, Tanaka S, et al. Association between plasma aldosterone and markers of tubular and glomerular damage in primary aldosteronism[J]. Clin Endocrinol (Oxf), 2021, 94(6): 920-926. doi:10.1111/cen.v94.6 URL
[29]	Reincke M, Rump LC, Quinkler M, et al. Risk factors associated with a low glomerular filtration rate in primary aldosteronism[J]. J Clin Endocrinol Metab, 2009, 94(3): 869-875. doi:10.1210/jc.2008-1851pmid:19116235
[30]	Kawashima A, Sone M, Inagaki N, et al. Renal impairment is closely associated with plasma aldosterone concentration in patients with primary aldosteronism[J]. Eur J Endocrinol, 2019, 181(3): 339-350. doi:10.1530/EJE-19-0047pmid:31319380
[31]	Hundemer GL, Vaidya A. Primary aldosteronism diagnosis and management[J]. Endocrinol Metab Clin North Am, 2019, 48(4): 681-700. doi:10.1016/j.ecl.2019.08.002 URL
[32]	Saiki A, Otsuki M, Tamada D, et al. Increased dosage of MRA improves BP and urinary albumin excretion in primary aldosteronism with suppressed plasma renin[J]. J Endocr Soc, 2021, 6(1): bvab174. doi:10.1210/jendso/bvab174 URL
[33]	Zennaro MC, Boulkroun S, Fernandes-Rosa FL. Pathogenesis and treatment of primary aldosteronism[J]. Nat Rev Endocrinol, 2020, 16(10): 578-589. doi:10.1038/s41574-020-0382-4
[34]	赵菁, 张进安. 原发性醛固酮增多症:一个常见的“罕见病”[J]. 上海医药, 2021, 42(8): 3-6.
[35]	Patel V, Joharapurkar A, Jain M. Role of mineralocorticoid receptor antagonists in kidney diseases[J]. Drug Dev Res, 2021, 82(3): 341-363. doi:10.1002/ddr.v82.3 URL
[36]	Chrissobolis S. Vascular consequences of aldosterone excess and mineralocorticoid receptor antagonism[J]. Curr Hypertens Rev, 2017, 13(1): 46-56. doi:10.2174/1573402113666170228151402pmid:28245785
[37]	中华医学会内分泌学分会. 原发性醛固酮增多症诊断治疗的专家共识(2020版)[J]. 中华内分泌代谢杂志, 2020, 36(9): 727-736.
[38]	Lechner B, Lechner K, Heinrich D, et al. Therapy of endocrine disease: medical treatment of primary aldosteronism[J]. Eur J Endocrinol, 2019, 181(4): R147-R153. doi:10.1530/EJE-19-0215
[39]	Mulatero P, Sechi LA, Williams TA, et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research[J]. J Hypertens, 2020, 38(10): 1929-1936. doi:10.1097/HJH.0000000000002520pmid:32890265
[40]	杨汉继, 郝娟, 张雨轩. 依普利酮通过下调VEGF表达抑制UUO模型大鼠对侧肾脏血管新生并减轻肾脏纤维化[J]. 中国病理生理杂志, 2021, 37(4): 688-695.

Research progress of chronic kidney injury in primary aldosteronism

RichHTML

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References40

Related Articles0

Recommended Articles

Metrics

Comments